Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
The rapid development of multiple vaccines providing strong protection from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
LJ Stevens, AJ Pruijssers, HW Lee… - Science translational …, 2022 - science.org
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Monoclonal antibodies with neutralizing activity against SARS-CoV-2 have demonstrated
clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing …
clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing …
SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
KH Dinnon III, SR Leist, K Okuda, H Dang… - Science translational …, 2022 - science.org
A subset of individuals who recover from coronavirus disease 2019 (COVID-19) develop
post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
D Li, GD Sempowski, KO Saunders… - Annual review of …, 2022 - annualreviews.org
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
Severe acute respiratory syndrome coronaviruses 1 (SARS-CoV) and 2 (SARS-CoV-2),
including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality …
including SARS-CoV-2 variants of concern, can cause deadly infections. The mortality …
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …
Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …
Drug combinations as a first line of defense against coronaviruses and other emerging viruses
The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-
equipped for future pandemics. While unprecedented strides have been made developing …
equipped for future pandemics. While unprecedented strides have been made developing …